Department of Medicine 5 – Haematology and Oncology

Desmoplastic small round cell tumors: Multimodality treatment and new risk factors (2019) Scheer M, Vokuhl C, Blank B, Hallmen E, Von Kalle T, Muenter M, Wessalowski R, et al. Journal article Efficient Elimination of Cells from Patients with Different AML Subtypes by Dual-Targeting Triplebody 33-16-123 (2019) Braciak T, Fenn N, Wildenhain S, Schiller C, Roskopf C, Schubert I, Jacob U, et al. Conference contribution To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps (2019) Boeltz S, Amini P, Anders HJ, Andrade F, Bilyy R, Chatfield S, Cichon I, et al. Journal article, Review article CircHIPK3 promotes proliferation and invasion in nasopharyngeal carcinoma by abrogating miR-4288-induced ELF3 inhibition (2019) Ke Z, Xie F, Zheng C, Chen D Journal article Design and Implementation of a Single Source Multipurpose Hospital-Wide Clinical Trial Registry. (2019) Sommer M, Kirchner M, Gulden C, Egloffstein S, Lux MP, Beckmann M, Mackensen A, Prokosch HU Journal article Design and Implementation of a Single Source Multipurpose Hospital-Wide Clinical Trial Registry (2019) Sommer M, Kirchner M, Gulden C, Egloffstein S, Lux MP, Beckmann M, Mackensen A, Prokosch HU Conference contribution Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study (2019) Fuchs M, Goergen H, Kobe C, Kuhnert G, Hitz F, Greil R, Sasse S, et al. Conference contribution BRAF inhibitor treatment in hairy cell leukemia: a long-term follow up study (2019) Liebers N, Roider T, Bohn JP, Pircher A, Ferstl B, Ebnoether M, Perker M, et al. Conference contribution Comparison of leukemia-associated immunophenotype (LAIP)-based and different-from-normal (DfN)-based analysis of measurable residual disease (MRD) in patients with AML (2019) Von Bonin M, Buecklein V, Krause S, Voelkl S, Rieger M, Berg T, Brendel C, et al. Conference contribution Impact of comorbidities on outcome with second and further line TKI treatment in patients with chronic myeloid leukemia (2019) Yildirim-Zuemruet G, Kohlbrenner K, Hehlmann R, Fabarius A, Baerlocher GM, Krause S, Burchert A, et al. Conference contribution